Volume 601 Issue 7894, 27 January 2022
Article | 23 November 2021 | Open Access
A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity
A phase I open-label trial evaluating the immunogencity, reactogenicity and safety of a peptide-based SARS-CoV-2 vaccine candidate to induce SARS-CoV-2-specific T cell responses.
Jonas S. Heitmann, Tatjana Bilich, Juliane S. Walz